Accolade, Inc. to Post FY2026 Earnings of ($1.01) Per Share, William Blair Forecasts (NASDAQ:ACCD)

Accolade, Inc. (NASDAQ:ACCD) – Analysts at William Blair issued their FY2026 earnings per share (EPS) estimates for shares of Accolade in a research report issued to clients and investors on Thursday, April 25th. William Blair analyst R. Daniels expects that the company will post earnings per share of ($1.01) for the year. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Accolade’s current full-year earnings is ($1.20) per share.

A number of other brokerages also recently issued reports on ACCD. Canaccord Genuity Group reduced their price objective on shares of Accolade from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Friday. Piper Sandler increased their price target on shares of Accolade from $12.00 to $15.00 and gave the stock an “overweight” rating in a report on Tuesday, January 9th. SVB Leerink assumed coverage on shares of Accolade in a research report on Monday, February 26th. They set an “outperform” rating and a $16.00 price target on the stock. Barclays lowered their target price on Accolade from $13.00 to $11.00 and set an “equal weight” rating for the company in a research note on Friday. Finally, Morgan Stanley cut their price target on shares of Accolade from $13.00 to $12.00 and set an “equal weight” rating on the stock in a report on Friday. Four research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $14.80.

Accolade Price Performance

ACCD stock opened at $8.19 on Monday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.35 and a current ratio of 2.35. The business has a 50-day simple moving average of $9.58 and a two-hundred day simple moving average of $9.94. Accolade has a 52-week low of $6.33 and a 52-week high of $15.36. The company has a market capitalization of $633.99 million, a P/E ratio of -6.16 and a beta of 2.08.

Accolade (NASDAQ:ACCD) last released its earnings results on Thursday, April 25th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.01. Accolade had a negative return on equity of 22.57% and a negative net margin of 24.09%. The business had revenue of $124.80 million during the quarter, compared to analysts’ expectations of $123.91 million. During the same quarter last year, the firm posted ($0.42) earnings per share. The firm’s revenue was up 26.1% on a year-over-year basis.

Hedge Funds Weigh In On Accolade

Institutional investors and hedge funds have recently modified their holdings of the stock. Nordea Investment Management AB boosted its stake in shares of Accolade by 1.4% in the 3rd quarter. Nordea Investment Management AB now owns 106,764 shares of the company’s stock worth $1,148,000 after buying an additional 1,423 shares during the last quarter. HighTower Advisors LLC purchased a new stake in Accolade during the third quarter valued at $2,354,000. Vanguard Group Inc. grew its position in Accolade by 3.1% in the third quarter. Vanguard Group Inc. now owns 5,283,858 shares of the company’s stock worth $55,903,000 after acquiring an additional 157,464 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. lifted its position in Accolade by 111.1% in the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,798,993 shares of the company’s stock worth $19,033,000 after buying an additional 946,970 shares during the last quarter. Finally, Olympiad Research LP bought a new position in Accolade during the 3rd quarter valued at about $171,000. 84.99% of the stock is currently owned by institutional investors.

About Accolade

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians.